# A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

> **NCT03258502** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 66 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** RV521
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03258502
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-19
- **Primary completion:** 2017-10-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258502, "A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03258502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*